ArticleLeukemia2021

Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.

Katja Weisel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.